SCHEMBL1109012

SCHEMBL1109012

NOc1ccc(O)c(=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 1/20 0.45
DBH P09172 3/20 0.42
MMP2 P08253 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
HSP90AA1 P07900 1/20 0.42
MAPK1 P28482 1/20 0.42
HDAC4 P56524 4/20 0.35
HDAC8 Q9BY41 4/20 0.35
HDAC2 Q92769 3/20 0.35
ALDH1A1 P00352 1/20 0.33
GAA P10253 1/20 0.33
THRB P10828 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
MCL1 Q07820 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23250710 0.76 HDAC4 (0.56) TYRKDM4EMEN1MAPTKMT2A
SCHEMBL2581495 0.72 TDP1 (0.39) MEN1MAPTKMT2ATDP1MAPK1
SCHEMBL916337 0.72 TYR (0.56) TYRDBHMMP2KDM4EMEN1
SCHEMBL23263219 0.71 SOS1 (0.50) TYRDBHMMP2KDM4EMEN1
SCHEMBL23250686 0.71 TYR (0.55) TYRMAPTKMT2AALDH1A1
SCHEMBL23250688 0.71 NQO1 (0.58) KDM4EMEN1MAPTKMT2ATDP1
SCHEMBL10339603 0.71 TYR (0.54) TYRDBHMMP2KDM4EMEN1
SCHEMBL2107857 0.71
SCHEMBL5524130 0.70 APP (0.43) MMP2KDM4EMEN1MAPTKMT2A
SCHEMBL23250716 0.70 PARP10 (0.44) TYRDBHMMP2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-8153440-B2 Methods for altering surface characteristics of microspheres LUMINEX CORPORATION (US) 2012-04-10 US disclosed
US-20110086431-A1 Methods for Altering Surface Characteristics of Microspheres LUMINEX CORPORATION (US) 2011-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB TYR 512/4885DBH 122/4885MMP2 4478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.